Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial

Autor: Stephen J. Thomas, John L. Perez, Stephen P. Lockhart, Subramanian Hariharan, Nicholas Kitchin, Ruth Bailey, Katherine Liau, Eleni Lagkadinou, Özlem Türeci, Ugur Şahin, Xia Xu, Kenneth Koury, Samuel S. Dychter, Claire Lu, Teresa C. Gentile, William C. Gruber

Publikováno v: Vaccine

Introduction Individuals with an underlying malignancy have high risk of poor COVID-19 outcomes. In clinical trials, COVID-19 vaccines were safe and efficacious against infection, hospitalization, and death, but most trials excluded participants with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cb5f1adc9988d2825bb0d5a9ad1defc
https://doi.org/10.1016/j.vaccine.2021.12.046

Mucosal immune response in BNT162b2 COVID-19 vaccine recipients

Autor: Lorenzo Azzi, Daniela Dalla Gasperina, Giovanni Veronesi, Mariam Shallak, Giuseppe Ietto, Domenico Iovino, Andreina Baj, Francesco Gianfagna, Vittorio Maurino, Daniele Focosi, Fabrizio Maggi, Marco Mario Ferrario, Francesco Dentali, Giulio Carcano, Angelo Tagliabue, Lorenzo Stefano Maffioli, Roberto Sergio Accolla, Greta Forlani

Publikováno v: EBioMedicine, Vol 75, Iss, Pp 103788-(2022)
EBioMedicine

Summary: Background: Although the BNT162b2 COVID-19 vaccine is known to induce IgG neutralizing antibodies in serum protecting against COVID-19, it has not been studied in detail whether it could generate specific immunity at mucosal sites, which rep

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cb4adce58d3fba0b1536acd3fc892eb
http://hdl.handle.net/11383/2130084

Influenza Management During the COVID-19 Pandemic: A Review of Recent Innovations in Antiviral Therapy and Relevance to Primary Care Practice

Autor: Warren A. Jones, Rita de Cassia Castro, Ruth Carrico, Henry L. Masters

Publikováno v: Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 5, Iss 6, Pp 974-991 (2021)

Seasonal influenza requires appropriate management to protect public health and resources. Decreasing the burden of influenza will depend primarily on increasing vaccination rates as well as prompt initiation of antiviral therapy within 48 hours of s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ddb885672724d24996574f46d22dbf8
https://pubmed.ncbi.nlm.nih.gov/34414356

Development and evaluation of a rapid nucleic acid amplification method to detect influenza A and B viruses in human respiratory specimens

Autor: Sonja Elf, Solveig Sjöblom, Kevin E. Eboigbodin, Minna Mäki, Karoliina Liikonen, Päivi Saavalainen, Pauliina Auvinen, Lisa Jahn

Publikováno v: Diagnostic Microbiology and Infectious Disease

Isothermal nucleic acid amplification methods can potentially shorten the amount of time required to diagnose influenza. We developed and evaluated a novel isothermal nucleic acid amplification method, RT-SIBA to rapidly detect and differentiate betw

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41c42d398e7bd60dfec6fac79fb70cdb
http://europepmc.org/articles/PMC7127616

New Proteomic Signatures to Distinguish Between Zika and Dengue Infections

Autor: Christine Vogel, Beni N. Balkaran, Elodie Ghedin, Moti Ramgopal, Liyun Liu, Maria T. Arévalo, Savita Purushwani, Shuvadeep Maity, Kristina Allgoewer, Lauren P. Lashua, Hyungwon Choi, Ted M. Ross, Alice Zhao

Publikováno v: Molecular & Cellular Proteomics : MCP

Distinguishing between Zika and dengue virus infections is critical for accurate treatment, but we still lack detailed understanding of their impact on their host. To identify new protein signatures of the two infections, we used next-generation prot

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60c3d88820e3983839e0ee8a0b1693c6
https://doi.org/10.1016/j.mcpro.2021.100052